- Keywords
- milvexian, žaludeční polypy,
- MeSH
- Stroke * drug therapy prevention & control MeSH
- Gabapentin pharmacology therapeutic use MeSH
- Genetic Markers MeSH
- Proton Pump Inhibitors * adverse effects MeSH
- Humans MeSH
- Drug-Related Side Effects and Adverse Reactions MeSH
- Pelvic Pain * drug therapy MeSH
- Polyps etiology MeSH
- Pyrimidines pharmacology therapeutic use MeSH
- Randomized Controlled Trials as Topic MeSH
- Triazoles pharmacology therapeutic use MeSH
- Stomach pathology MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- MeSH
- Analgesics MeSH
- Anesthetics, Local administration & dosage therapeutic use MeSH
- Gabapentin administration & dosage therapeutic use MeSH
- Quality of Life MeSH
- Humans MeSH
- Lidocaine administration & dosage therapeutic use MeSH
- Neuralgia, Postherpetic * diagnosis drug therapy prevention & control MeSH
- Aged MeSH
- Transdermal Patch MeSH
- Herpes Zoster Vaccine MeSH
- Check Tag
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
- Keywords
- syndrom bolestiplných dolních končetin a pohyblivých prstců,
- MeSH
- Pain diagnosis pathology MeSH
- Lower Extremity * pathology MeSH
- Adult MeSH
- Gabapentin therapeutic use MeSH
- Humans MeSH
- Nervous System Diseases * diagnosis MeSH
- Movement Disorders MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
Na úrovni farmakokinetiky jsou lékové interakce antiepileptik spojeny obvykle s enzymatickou indukcí nebo inhibicí. Méně časté jsou interakce v oblasti absorpce, vazby na plazmatické bílkoviny nebo renální exkrece. Farmakodynamické interakce antiepileptik s dalšími látkami se zřídka týkají synergismu s možností snížení dávek, spíše se zvyšuje incidence vedlejších účinků. Čistě farmakodynamické interakce byly popsány u oxcarbazepinu, perampanelu a pregabalinu.
Drug interactions of antiepileptic drugs are mostly connected with enzymatic induction or inhibition. The interaction on level of absorption, plasma-protein binding of renal excretion is less frequent. Pharmacodynamic interaction of antiepileptics with other drugs is seldom synergistic with a possibility of declination of dose. The increase of adverse drug reactions is more common. Purely pharmacodynamic interaction was described with oxcarbazepin, perampanel and pregabalin. The new antiepileptics have lower interaction potential - most of them are excreted either via kidney or extrahepatal (e. g. gabapentin, lacosamide, levetiracetam, topiramate, vigabatrin). Enzymatic induction is either not present or minimal. The inductive effect is necessary to be taken into account in carbamazepine, phenytoin and phenobarbital. Inhibitive effect is held in valproic acid and felbamate. The interactive potential among newer antiepileptics is the highest in lamotrigine, oxcarbazepine and rufinamide. Drug interactions were not found in lacosamide, pregabalin, stiripentol and vigabatrin.
- MeSH
- Anticonvulsants * pharmacokinetics blood MeSH
- Phenobarbital pharmacokinetics MeSH
- Phenytoin pharmacokinetics MeSH
- Gabapentin pharmacokinetics MeSH
- Carbamazepine pharmacokinetics MeSH
- Valproic Acid pharmacokinetics MeSH
- Lamotrigine pharmacokinetics MeSH
- Drug Interactions * MeSH
- Humans MeSH
- Primidone pharmacokinetics MeSH
- Topiramate pharmacokinetics MeSH
- Check Tag
- Humans MeSH
Na úrovni farmakokinetiky jsou lékové interakce antiepileptik spojeny obvykle s enzymatickou indukcí nebo inhibicí. Méně časté jsou interakce v oblasti absorpce, vazby na plazmatické bílkoviny nebo renální exkrece. Farmakodynamické interakce antiepileptik s dalšími látkami se zřídka týkají synergismu s možností snížení dávek, spíše se zvyšuje incidence vedlejších účinků. Čistě farmakodynamické interakce byly popsány u oxcarbazepinu, perampanelu a pregabalinu. Nová antiepileptika mají nižší interakční potenciál - řada z nich se vylučuje renálně nebo extrahepatálně (např. gabapentin, lacosamid, levetiracetam, topiramát, vigabatrin). K enzymatické indukci pak nedochází vůbec nebo zcela minimálně. Ze starších látek lze počítat s projevem indukčního efektu u karbamazepinu, fenytoinu a fenobarbitalu. Inhibiční efekt se uplatňuje u valproátu a felbamátu. Z nových látek je interakční potenciál nejvyšší u lamotriginu, oxcarbazepinu a rufinamidu. Lékové interakce nebyly popsány u lacosamidu, pregabalinu, stiripentolu a vigabatrinu.
Drug interactions of antiepileptic drugs are mostly connected with enzymatic induction or inhibition. The interaction on level of absorption, plasma-protein binding of renal excretion is less frequent. Pharmacodynamic interaction of antiepileptics with other drugs is seldom synergistic with a possibility of declination of dose. The increase of adverse drug reactions is more common. Purely pharmacodynamic interaction was described with oxcarbazepin, perampanel and pregabalin. The new antiepileptics have lower interaction potential - most of them are excreted either via kidney or extrahepatal (e. g. gabapentin, lacosamide, levetiracetam, topiramate, vigabatrin). Enzymatic induction is either not present or minimal. The inductive effect is necessary to be taken into account in carbamazepine, phenytoin and phenobarbital. Inhibitive effect is held in valproic acid and felbamate. The interactive potential among newer antiepileptics is the highest in lamotrigine, oxcarbazepine and rufinamide. Drug interactions were not found in lacosamide, pregabalin, stiripentol and vigabatrin.
- MeSH
- Anticonvulsants * pharmacokinetics blood MeSH
- Phenobarbital pharmacokinetics MeSH
- Phenytoin pharmacokinetics MeSH
- Gabapentin pharmacokinetics MeSH
- Carbamazepine pharmacokinetics MeSH
- Valproic Acid pharmacokinetics MeSH
- Lamotrigine pharmacokinetics MeSH
- Drug Interactions * MeSH
- Humans MeSH
- Primidone pharmacokinetics MeSH
- Topiramate pharmacokinetics MeSH
- Check Tag
- Humans MeSH
- MeSH
- Antidepressive Agents therapeutic use MeSH
- Anticonvulsants therapeutic use MeSH
- Diabetic Neuropathies * drug therapy MeSH
- Duloxetine Hydrochloride administration & dosage therapeutic use MeSH
- Gabapentin administration & dosage therapeutic use MeSH
- Diabetes Complications drug therapy MeSH
- Thioctic Acid therapeutic use MeSH
- Humans MeSH
- Neuralgia * etiology drug therapy MeSH
- Pregabalin administration & dosage therapeutic use MeSH
- Tramadol administration & dosage therapeutic use MeSH
- Check Tag
- Humans MeSH
Multimodální analgezie je založena na předpokladu, že benefity kombinace léků převáží nad riziky. Perioperační podávání gabapentinoidů má významné nežádoucí účinky. Gabapentinoidy v kombinaci s opioidy vykazují dokonce vyšší respirační riziko než samotné opioidy. Rutinní perioperační podávání gabapentinoidů již není doporučeno. Je velmi nepravděpodob né, že by nové klinické studie ohledně hodnocení analgetického benefitu gabapentinoidů na pooperační bolest poskytly nějaké nové důkazy.
Multimodal analgesia is predicated on interactions of medicines whereby benefits of combination exceed the risks. Perioperative gabapentinoids have significant adverse effects. Gabapentinoids, when combined with opioids, confer even greater respiratory risk than opioids alone. Routine perioperative administration of gabapentinoids is not more recommended. New clinical trials to evaluate analgesic benefits of gabapentinoids on postoperative pain are very unlikely to provide any new evidence.
- Keywords
- gabapentinoidy,
- MeSH
- Analgesia methods MeSH
- gamma-Aminobutyric Acid analogs & derivatives therapeutic use MeSH
- Gabapentin * history adverse effects therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Humans MeSH
- Drug-Related Side Effects and Adverse Reactions MeSH
- Perioperative Period * MeSH
- Pain, Postoperative drug therapy MeSH
- Pregabalin * history adverse effects therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
- MeSH
- Analgesics administration & dosage classification MeSH
- Pain * drug therapy MeSH
- Back Pain drug therapy MeSH
- Gabapentin adverse effects therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Middle Aged MeSH
- Humans MeSH
- Pain Management * methods MeSH
- Meloxicam administration & dosage MeSH
- Analgesics, Opioid administration & dosage pharmacology classification metabolism MeSH
- Pregabalin administration & dosage MeSH
- Tramadol administration & dosage pharmacology metabolism MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
- Review MeSH
- MeSH
- Amitriptyline therapeutic use MeSH
- Buprenorphine administration & dosage therapeutic use MeSH
- Gabapentin administration & dosage adverse effects therapeutic use MeSH
- Carboplatin administration & dosage adverse effects therapeutic use MeSH
- Carcinosarcoma diagnosis therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Lynch Syndrome II diagnosis complications MeSH
- Uterine Neoplasms surgery therapy MeSH
- Neuralgia * chemically induced drug therapy MeSH
- Drug-Related Side Effects and Adverse Reactions drug therapy MeSH
- Analgesics, Opioid * pharmacology therapeutic use MeSH
- Paclitaxel administration & dosage adverse effects therapeutic use MeSH
- Polyneuropathies chemically induced drug therapy MeSH
- Antineoplastic Agents adverse effects MeSH
- Tapentadol administration & dosage therapeutic use MeSH
- Transdermal Patch MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
Diabetická polyneuropatia je najčastejšou komplikáciou diabetu a súčasne najčastejšou príčinou syndrómu diabetickej nohy a bolesti pacientov s diabetes mellitus. V klinickej praxi ide stále o nedostatočne, resp. neskoro diagnostikované ochorenie, pričom práve terapeutický zásah v skorých štádiách ochorenia môže spomaliť (prípadne až zastaviť) progresiu polyneuropatie. Práca poskytuje súhrn aktuálnych možností prevencie a liečby diabetickej polyneuropatie a podáva prehľad o liekoch a nutraceutických produktoch, ktoré boli alebo sú v klinickom skúšaní.
Diabetic polyneuropathy is the most frequent complication of diabetes mellitus and at the same time the most common cause of diabetic foot syndrome and pain in patients with diabetes. This disorder is still being diagnosed insufficiently and too late in many cases. Therapeutic intervention in early stages could slow down (or completely stop) progression of the neuropathy. Presented paper reviews current possibilities of prevention and therapy of diabetic polyneuropathy as well as pharmaceuticals and nutraceuticals that were, or still are involved in clinical trials.
- MeSH
- Acetylcarnitine therapeutic use MeSH
- Amitriptyline administration & dosage therapeutic use MeSH
- Diabetic Neuropathies * therapy MeSH
- Duloxetine Hydrochloride administration & dosage therapeutic use MeSH
- Gabapentin administration & dosage therapeutic use MeSH
- Thioctic Acid administration & dosage therapeutic use MeSH
- Humans MeSH
- Neuralgia therapy MeSH
- Polyneuropathies etiology therapy MeSH
- Pregabalin administration & dosage therapeutic use MeSH
- Tapentadol administration & dosage therapeutic use MeSH
- Thiamine administration & dosage therapeutic use MeSH
- Tramadol administration & dosage therapeutic use MeSH
- Vitamin B Complex therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
